Achieve Life Sciences is trading at $7.07 (+5.68%) after Morgan Stanley initiated coverage on August 13, 2026, with an Overweight rating and a $13.00 price target.
- The August 11 earnings update highlighted $187.3 million in cash.
- The company plans a fourth-quarter 2026 NDA resubmission.
- Broader markets are also positive, but the analyst initiation is the clearest company-specific catalyst.